TABLE 1.
Characteristics and Vaccination Status of Children With a History of MIS-C Who Were COVID-19 Vaccine-eligible* at Time of Interview and/or Chart Abstraction, N = 163
| Vaccinated, n, (%) (n = 51) | Unvaccinated, n, (%) (n = 112) | P † | |
|---|---|---|---|
| Age group (y)‡ | |||
| 5–11 | 13 (25) | 71 (63) | <0.001 |
| 12–15 | 16 (31) | 24 (21) | 0.242 |
| 16–20 | 22 (43) | 17 (15) | <0.001 |
| Sex | |||
| Male | 38 (75) | 61 (54) | 0.015 |
| Race/ethnicity§ | |||
| Hispanic | 17 (33) | 18 (16) | 0.027 |
| Non-Hispanic Black | 17 (33) | 61 (54) | 0.079 |
| Non-Hispanic White | 13 (25) | 26 (23) | 0.432 |
| Non-Hispanic other race¶ | 2 (4) | 5 (4) | 0.488 |
| Location | |||
| Institution 1 | 46 (90) | 94 (84) | 0.287 |
| Institution 2 | 5 (10) | 13 (12) | 0.733 |
| Institution 3 | 0 (0) | 5 (4) | 0.326 |
| Underlying medical conditions | |||
| None | 23 (45) | 72 (64) | 0.021 |
| Obesity | 22 (43) | 31 (28) | 0.051 |
| Other‖ | 12 (24) | 16 (14) | 0.814 |
| Severity of previous MIS-C illness | |||
| Cardiac MIS-C involvement** | 24 (47) | 63 (56) | 0.275 |
| Intensive care unit admission | 29 (57) | 62 (55) | 0.858 |
| Life support†† | 23 (45) | 50 (45) | 0.957 |
| Median hospital length of stay, d (IQR) | 6 (4–8) | 6 (4–8) | 0.550 |
| Median time from MIS-C hospital discharge to initial interview for those interviewed, mo (IQR) | 11 (9–14) | 12 (10–14) | 0.858 |
Vaccine eligible: age ≥12 years if interview or chart abstraction completed before November 2, 2021, and age ≥5 years if interview or chart abstraction completed on or after November 2, 2021. For those interviewed, date of most recent interview was used to calculate eligibility for vaccination.
Chi square or Fisher’s Exact two-sided P value if cell <5 for categorical variables; Kruskal–Wallis for continuous variables.
Age calculated at time of most recent interview or chart abstraction.
Race was unknown for 2 individuals in the vaccinated group and 2 individuals in the unvaccinated group.
Other race = Asian, Native Hawaiian, multiple and other.
Conditions in the vaccinated group: chronic lung disease (n = 8; one also with sickle cell disease); Klippel-Feil syndrome (n = 1); congenital heart disease (n = 1), immunocompromising condition (n = 1), Trisomy 21 and obstructive sleep apnea (n = 1). Conditions in the unvaccinated group: chronic lung disease (n = 13; one also with vertebral defects, anal atresia, cardiac defects, tracheoesophageal fistula, renal anomalies and limb abnormalities (VACTERL) syndrome and one also with Trisomy 21, congenital heart disease and obstructive sleep apnea), congenital heart disease (n = 1), Trisomy 21 (n = 1) and type 2 diabetes (n = 1).
Cardiac involvement: congestive heart failure, myocarditis, pericarditis noted in the chart or an echocardiogram finding (coronary aneurysm, coronary artery dilation or cardiac dysfunction).
Life support: receipt of vasopressors, intubation/mechanical ventilation or extracorporeal membranous oxygenation.